Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
HER2+
100%
Molecular Features
100%
Immunological Characteristics
100%
Worse Prognosis
100%
Endometrioid Endometrial Cancer
100%
Immune Microenvironment
100%
HER2 Status
57%
HER2+ Tumors
57%
Tumor
42%
Microsatellite Stable
42%
Targeted Therapy
28%
Pathway Activation
28%
Uterine Serous Carcinoma
28%
Mitogen-activated Protein Kinase
28%
HER2 Positivity
28%
Gene Expression
14%
Potential Gains
14%
Patient Demographics
14%
Human Epidermal Growth Factor Receptor 2 (HER2)
14%
Patient Outcomes
14%
Targeted Immunotherapy
14%
Immunohistochemistry
14%
Life Sciences
14%
Transcriptomics
14%
Molecular Alterations
14%
Cancer Tumor
14%
Whole Exome Sequencing
14%
TP53 mutation
14%
Immune Infiltration
14%
Next-generation Sequencing
14%
Overall Survival
14%
Molecular Landscape
14%
Loss of Heterozygosity
14%
Genomic Features
14%
Phoenix
14%
PTEN mutation
14%
Defining Characteristic
14%
Survival Outcomes
14%
Whole Transcriptome Sequencing
14%
CTNNB1 mutation
14%
Life-science Databases
14%
Immune Checkpoint Genes
14%
Kaplan-Meier Analysis
14%
Biochemistry, Genetics and Molecular Biology
Mitogen-Activated Protein Kinase
100%
Microsatellite
100%
Immune Microenvironment
100%
Targeted Therapy
66%
Exome Sequencing
33%
Loss of Heterozygosity
33%
Next Generation Sequencing
33%
RNA Sequencing
33%
Cell Infiltration
33%
Immune Checkpoints
33%
Gene Expression
33%
Immunocompetent Cell
33%
Overall Survival
33%
Transcriptomics
33%
Genomics
33%
Medicine and Dentistry
Tumor
100%
Uterine Cancer
100%
Mitogen-Activated Protein Kinase
37%
Targeted Therapy
25%
Uterine Serous Carcinoma
25%
RNA Sequencing
12%
Gene Expression
12%
Patient Population
12%
Exome Sequencing
12%
Transcriptomics
12%
Immunohistochemistry
12%
Overall Survival
12%
Kaplan Meier Method
12%
Heterozygosity
12%
Next Generation Sequencing
12%
Immune Cell Infiltration
12%
Immunotherapy
12%
Chemiluminescence Immunoassay
12%